AAZ-A-154
http://dbpedia.org/resource/AAZ-A-154 an entity of type: Thing
AAZ-A-154 is a novel isotryptamine derivative which acts as a 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at UCDavis. Animal studies suggest that it produces antidepressant effects without the psychedelic action typical of drugs from this class. In tests, AAZ-A-154 had antidepressant effects in mice without causing the head-twitch response linked to hallucinogenic effects. Due to the rapidly-induced and enduring neuroplasticity, AAZ-A-154 is a member of the class of compounds known as non-hallucinogenic psychoplastogens. This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.
rdf:langString
rdf:langString
AAZ-A-154
xsd:integer
67809523
xsd:integer
1120265029
xsd:integer
14
xsd:integer
20
xsd:integer
-1
xsd:integer
2
xsd:integer
1
xsd:integer
154694212
rdf:langString
CN[C@H]Cn1ccc2ccOC
xsd:integer
1
rdf:langString
KHEUWLQKCXGVEL-LLVKDONJSA-N
rdf:langString
AAZ-A-154 is a novel isotryptamine derivative which acts as a 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at UCDavis. Animal studies suggest that it produces antidepressant effects without the psychedelic action typical of drugs from this class. In tests, AAZ-A-154 had antidepressant effects in mice without causing the head-twitch response linked to hallucinogenic effects. Due to the rapidly-induced and enduring neuroplasticity, AAZ-A-154 is a member of the class of compounds known as non-hallucinogenic psychoplastogens. This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.
xsd:nonNegativeInteger
3147
xsd:string
154694212